Abstract: In one aspect, the present disclosure provides compounds which inhibit a coronavirus main protease. In another aspect, the present disclosure provides a method of treating, ameliorating and/or preventing a coronavirus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of the disclosure. In some embodiments, the method prevents or treats COVID-19 in the subject.

Abstract: Small molecules acting through the ligand binding domain of nuclear receptor TLX (NR2E1) are disclosed, as well as the use thereof for promoting neurogenesis and treating disorders associated with nuclear receptor TLX, including neurological disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I and Formula II as described herein, and pharmaceutically acceptable salts or isomers thereof.

Abstract: The present disclosure relates to compounds which inhibit one or more members of the neurotrophic receptor tyrosine kinase (NTRK) family (i.e., NTRK1, NTRK2, and/or NTRK3), and pharmaceutical compositions thereof. In another aspect, the present disclosure provides a method of treating, preventing, and/or ameliorating at least one disease and/or disorder selected from the group consisting of endometriosis, cancer, and pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of the present disclosure and/or a pharmaceutical composition of the present disclosure.

Abstract: Small molecules acting through the ligand binding domain of nuclear receptor TLX (NR2E1) are disclosed, as well as the use thereof for promoting neurogenesis and treating disorders associated with nuclear receptor TLX, including neurological disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula II as described herein, and pharmaceutically acceptable salts or isomers thereof.

Abstract: In one aspect, the present disclosure relates to compounds which inhibit one or more ?-lactamases and/or penicillin binding proteins (PBPs), and pharmaceutical compositions thereof. In another aspect, the present disclosure provides a method of treating, preventing, and/or ameliorating a bacterial infection in a subject, the method comprising administering to the subject a therapeutically effective amount of at least one compound of the present disclosure and/or at least one pharmaceutical composition of the present disclosure. In certain embodiments, the ?-lactamase is selected from the group consisting of NDM-1, KPC-2, and OXA-48. In certain embodiments, the PBP is PBP-3.

Abstract: In one aspect, the present disclosure provides compounds which inhibit a coronavirus main protease. In another aspect, the present disclosure provides a method of treating, ameliorating and/or preventing a coronavirus infection in a subject, the method comprising administering to the subject a therapeutically effective amount of a compound of the disclosure. In some embodiments, the method prevents or treats COVID-19 in the subject.

Abstract: G protein-coupled receptor (GPCR) regulators and methods for their use are provided herein. The GPCR regulators described herein are useful in treating and/or preventing conditions or diseases associated with a GPCR, including ageing, cancer, cardiovascular disorders, hematologic disorders, infectious diseases, inflammatory diseases, metabolic diseases, neurodegenerative disorders, respiratory diseases, or urological disorders. Also provided are methods of regulating a G protein-coupled receptor in a cell using the compounds and compositions described herein.

Abstract: Small molecules acting through the ligand binding domain of nuclear receptor TLX (NR2E1) are disclosed, as well as the use thereof for promoting neurogenesis and treating disorders associated with nuclear receptor TLX, including neurological disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula II as described herein, and pharmaceutically acceptable salts or isomers thereof.